New York State Common Retirement Fund grew its position in AxoGen, Inc. (NASDAQ:AXGN - Free Report) by 63.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 69,629 shares of the medical equipment provider's stock after purchasing an additional 27,101 shares during the quarter. New York State Common Retirement Fund owned approximately 0.16% of AxoGen worth $1,147,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Quest Partners LLC boosted its holdings in AxoGen by 23,066.7% in the 3rd quarter. Quest Partners LLC now owns 2,085 shares of the medical equipment provider's stock worth $29,000 after buying an additional 2,076 shares during the period. R Squared Ltd purchased a new position in shares of AxoGen in the fourth quarter valued at about $30,000. Oppenheimer & Co. Inc. bought a new position in shares of AxoGen in the third quarter worth about $156,000. Quantbot Technologies LP purchased a new stake in shares of AxoGen during the third quarter worth about $165,000. Finally, BNP Paribas Financial Markets grew its position in shares of AxoGen by 238.6% during the third quarter. BNP Paribas Financial Markets now owns 12,284 shares of the medical equipment provider's stock worth $172,000 after purchasing an additional 8,656 shares in the last quarter. 80.29% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
Several research analysts have weighed in on the company. Canaccord Genuity Group upped their price target on AxoGen from $22.00 to $26.00 and gave the stock a "buy" rating in a research note on Wednesday, February 26th. Cantor Fitzgerald restated an "overweight" rating and set a $24.00 target price on shares of AxoGen in a research report on Wednesday. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $20.75.
Check Out Our Latest Stock Report on AxoGen
Insider Activity
In other news, Director Amy Mcbride Wendell sold 5,000 shares of the business's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $20.02, for a total value of $100,100.00. Following the sale, the director now directly owns 97,899 shares in the company, valued at $1,959,937.98. The trade was a 4.86 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 7.00% of the company's stock.
AxoGen Price Performance
NASDAQ AXGN traded down $0.19 during trading on Friday, hitting $17.58. 204,328 shares of the stock traded hands, compared to its average volume of 547,202. The company has a quick ratio of 2.47, a current ratio of 3.74 and a debt-to-equity ratio of 0.67. AxoGen, Inc. has a 12-month low of $5.55 and a 12-month high of $21.00. The firm has a 50-day simple moving average of $17.90 and a 200-day simple moving average of $15.26. The company has a market capitalization of $779.57 million, a P/E ratio of -54.81 and a beta of 1.00.
AxoGen Profile
(
Free Report)
AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.
Further Reading
Before you consider AxoGen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AxoGen wasn't on the list.
While AxoGen currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
